Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ASTX-660 |
Synonyms | |
Therapy Description |
ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASTX-660 | ASTX660|ASTX 660 | SMAC Mimetic 8 | ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287, PMID: 31900279). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | ASTX-660 | Phase I | Actionable | In a Phase I trial, ASTX660 treatment was well-tolerated, and resulted in no objective responses in heavily pretreated advanced solid tumor (n=43) and lymphoma (n=2) patients with stable disease as the best response in 29% (10/35) of evaluable patients, and a median progression-free survival of 55 days and median overall survival of 265 days in the entire cohort, and clinical improvement in a patient with cutaneous T-cell lymphoma (PMID: 31900279; NCT02503423). | 31900279 |
Unknown unknown | triple-receptor negative breast cancer | not applicable | ASTX-660 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ASTX-660 inhibited growth of triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (Cancer Res 2016;76(14 Suppl):Abstract nr 1287). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04155580 | Phase I | ASTX-660 ASTX-660 + Decitabine and Cedazuridine | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT02503423 | Phase Ib/II | ASTX-660 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 1 |